Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
InChI
InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Molecular Formula | C8H15N7O2S3 |
Molecular Weight | 337.445 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00927Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Sources: http://www.drugbank.ca/drugs/DB00927
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/famotidine.html
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8204567
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1941 Sources: http://www.drugbank.ca/drugs/DB00927 |
0.3 µM [IC50] | ||
Target ID: CHEMBL2073673 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16141367 |
6.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
|||
Curative | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
|||
Primary | PEPCID Approved UsePEPCID is indicated in:
1. Short-term treatment of active duodenal ulcer.
2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer.
3. Short-term treatment of active benign gastric ulcer.
4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm
treatment of patients with symptoms of GERD
PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy
5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple
endocrine adenomas) Launch Date1986 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
73 ng/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
424 ng × h/mL |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
82.5% |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
FAMOTIDINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.5 mg/kg 2 times / day steady, oral Recommended Dose: 0.5 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.5 mg/kg, 2 times / day Sources: |
unhealthy, 11 - 15 years Health Status: unhealthy Age Group: 11 - 15 years Sex: M Sources: |
|
80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Other AEs: Dizziness, Dry skin... Other AEs: Dizziness (grade 1, 2 patients) Sources: Dry skin (grade 1, 1 patient) Insomnia (grade 1, 1 patient) Gastrointestinal disorder (NOS) (grade 1, 1 patient) Forgetfulness (grade 1, 1 patient) |
1 mg/kg 1 times / day steady, intravenous Recommended Dose: 1 mg/kg, 1 times / day Route: intravenous Route: steady Dose: 1 mg/kg, 1 times / day Sources: |
unhealthy, 6 - 15 years Health Status: unhealthy Age Group: 6 - 15 years Sex: M Sources: |
|
26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Other AEs: Anemia, Nausea... Other AEs: Anemia (2 patients) Sources: Nausea (6 patients) Dyspepsia (5 patients) Diarrhea (5 patients) Constipation (4 patients) Abdominal pain upper (3 patients) Gastroesophageal reflux disease (2 patients) Vomiting (2 patients) Stomach discomfort (2 patients) Abdominal pain (2 patients) Edema peripheral (2 patients) Arthralgia (1 patient) Back pain (2 patients) Headache (3 patients) Hypertension (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry skin | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Forgetfulness | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Gastrointestinal disorder (NOS) | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Insomnia | grade 1, 1 patient | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Dizziness | grade 1, 2 patients | 80 mg 3 times / day steady, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: steady Dose: 80 mg, 3 times / day Sources: |
unhealthy, 20 - 70 years Health Status: unhealthy Age Group: 20 - 70 years Sex: M+F Sources: |
Arthralgia | 1 patient | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Abdominal pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Anemia | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Back pain | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Edema peripheral | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Gastroesophageal reflux disease | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Stomach discomfort | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Vomiting | 2 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Abdominal pain upper | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Headache | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Hypertension | 3 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Constipation | 4 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Diarrhea | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Dyspepsia | 5 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Nausea | 6 patients | 26.6 mg 3 times / day steady, oral Highest studied dose Dose: 26.6 mg, 3 times / day Route: oral Route: steady Dose: 26.6 mg, 3 times / day Sources: |
unhealthy, adult |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 6.0 |
weak | likely (co-administration study) Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value Page: 6.0 |
||
yes [IC50 114 uM] | ||||
yes [IC50 28 uM] | ||||
yes [IC50 6.7 uM] | ||||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
Page: 1.0 |
yes [Inhibition 100 uM] | |||
yes [Ki 0.6 uM] | ||||
yes [Ki 9.7 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs. | 1991 Apr |
|
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. | 1992 Mar |
|
[Tolerance of famotidine. Study of network of sentinel physicians in pharmaco-vigilance]. | 1992 May-Jun |
|
[A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy]. | 2000 Aug |
|
Acute cholestatic hepatitis in a child treated with famotidine. | 2000 Dec |
|
Amantadine-induced cortical myoclonus. | 2001 Jan 23 |
|
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment. | 2001 May |
|
Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine. | 2001 Oct |
|
Delirium following a switch from cimetidine to famotidine. | 2001 Sep |
|
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats. | 2002 Apr |
|
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans. | 2002 Apr |
|
Histamine regulation of interleukin-18-initiating cytokine cascade is associated with down-regulation of intercellular adhesion molecule-1 expression in human peripheral blood mononuclear cells. | 2002 Jan |
|
[Use of H2-receptor blocker famotidine (quamatel) in anesthesiology for cardiopulmonary bypass surgery]. | 2002 Jan-Feb |
|
H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. | 2002 Jul |
|
Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation. | 2002 Jun |
|
Randomized comparative study of omeprazole and famotidine in reflux esophagitis. | 2002 Sep |
|
Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1- and B7.1-dependent manner. | 2003 Feb |
|
Omeprazole-induced acute interstitial nephritis. | 2003 Feb 21 |
|
[A successfully treated case of intraoperative latex anaphylaxis during abdominal aorta aneurysm resection]. | 2003 Jan |
|
Radioprotective properties of histamine H2 receptor antagonists: present and future prospects. | 2003 Jun |
|
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin. | 2003 Jun |
|
On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion. | 2003 Jun |
|
Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. | 2003 May 1 |
|
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study. | 2004 Dec |
|
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. | 2004 May |
|
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). | 2004 Oct 25 |
|
Effects of cimetidine-like drugs on recombinant GABAA receptors. | 2004 Oct 8 |
|
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. | 2004 Sep |
|
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis. | 2005 Feb |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration. | 2005 Jun |
|
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. | 2005 Jun |
|
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. | 2005 Jun |
|
Effect of preoperative short course famotidine on TILs and survival in breast cancer. | 2005 Oct-Dec |
|
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy). | 2006 Dec |
|
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. | 2006 Mar |
|
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine. | 2006 May |
|
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease. | 2006 Oct |
|
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies. | 2006 Oct 3 |
|
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial. | 2007 Jan |
|
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors. | 2007 Oct |
|
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease. | 2008 |
|
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina? | 2008 Aug |
|
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats. | 2008 Winter |
|
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis. | 2009 |
|
Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor. | 2009 |
|
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach. | 2009 Dec |
|
Hepatitis following famotidine: a case report. | 2009 Jan 27 |
|
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). | 2009 Jun |
|
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. | 2010 Apr |
Patents
Sample Use Guides
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23857299
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:11:48 GMT 2025
by
admin
on
Mon Mar 31 18:11:48 GMT 2025
|
Record UNII |
5QZO15J2Z8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A02BA03
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
NDF-RT |
N0000175784
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
WHO-VATC |
QA02BA03
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
NCI_THESAURUS |
C29702
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
WHO-ATC |
A02BA53
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
LIVERTOX |
NBK548228
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
WHO-VATC |
QA02BA53
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
||
|
NDF-RT |
N0000000151
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Famotidine
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
DTXSID5023039
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
DB00927
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
757810
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
D015738
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
SUB07503MIG
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
5217
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
100000092363
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
7074
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
3325
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
m5241
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL902
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
4278
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | RxNorm | ||
|
FAMOTIDINE
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
1269200
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
4975
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
1129
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
W-33
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
3572
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
C29045
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
5QZO15J2Z8
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY | |||
|
76824-35-6
Created by
admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
USP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
EXCRETED UNCHANGED |
Following IV administration
URINE
|
||
|
TARGET->INVERSE AGONIST |
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
|
||
|
TRANSPORTER -> INHIBITOR |
IC50
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET->INVERSE AGONIST |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> NON-INHIBITOR |
IC50
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||